期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨联合半量CAG方案治疗老年人急性髓系白血病三例并文献复习 被引量：5

原文传递
导出
摘要 目的 探讨老年人急性髓系白血病（AML）新的有效治疗方法.方法 应用地西他滨联合半量CAG方案治疗3例老年AML患者,通过对临床资料、实验室检查指标、诊疗经过及转归进行分析,并进行相关文献复习和讨论.结果 3例患者均为年龄＞ 60岁的老年人AML,均有不同程度的基础疾病,为中高危预后,且有1例患者有前驱血液病史,3例患者经地西他滨联合半量CAG方案化疗后,均获得完全缓解,治疗期间并发症可控.结论 地西他滨联合半量CAG方案是老年AML患者安全、有效的治疗选择.
作者 张文静 师锦宁 桂琳 张婷 闫薛
机构地区 南京医科大学附属江宁医院血液科
出处 《白血病．淋巴瘤》 CAS 2013年第11期686-688,共3页 Journal of Leukemia & Lymphoma
关键词 急性髓系白血病 地西他滨 预激疗法
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patienls. J Clin Oneol, 2007, 25: 1908-1915. 被引量：1
  • 2Baylin SB, Herman JG, Graft JR. Alterations in DNA methylation: a fundmnental aspect of neoplasia. Adv Cancer Res, 1998, 72: 141-196. 被引量：1
  • 3Christman JK. 5-Azaeytidine and 5-aza-2'-deoxycytidine as inhibitnrs of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene, 2002, 21: 5483-5495. 被引量：1
  • 4Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Aead Sci U S A, 2010, 107: 7473- 7478. 被引量：1
  • 5Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am, 2010, 24: 317-330. 被引量：1
  • 6Yan P, Frankhouser D, Murphy M, et al. Genuine-wide methylatiun profiling in decitaline-treated patients with acute myeloid leukemia. Blxt, 2012, 120: 2466-2474. 被引量：1
  • 7Bryan J, Kantarjian H, Garcia-Manero G, et al.Pharmaeokinetie evaluation of deeitabine for the treatment of leukemia. Expert Opin Drug Metab Toxieol, 2011, 7: 661-672. 被引量：1
  • 8谢翔,赵腾,李广伦,杨颉,崔中光,冯献启,王伟,刘竹珍,许宏,史雪,汪洪毅,吴少玲,赵春亭,赵洪国.地西他滨四天方案治疗骨髓增生异常综合征及老年人急性髓系白血病[J].白血病．淋巴瘤,2012,21(10):622-623. 被引量：3
  • 9Cashen AF, Schiller GJ, O'Donnell MR, et al. Muhicenter, Phase II Study of Decitahine for the First-Line Treatment of Older Patients With Acute Mye|oid Leukemia. J Clin Oncol, 2010, 28: 556-561. 被引量：1
  • 10Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigeneticpriming with decitabine prior to standard induction chemotherapy for patients with AML. Blood, 2011, 118: 1472-1480. 被引量：1

二级参考文献13

  • 1Nimer SD. Myelodysplastic syndromes. Blood, 2008, 111:4841-4851. 被引量：1
  • 2Plimaek ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoiefic malignancies. Leuk Lymphoma, 2007, 48: 1472-1480. 被引量：1
  • 3Solomon PR, Munirajan AK, Tsuchida N, et al. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic&prognostic implication. Indian J Med Res, 2008, 127:52- 57. 被引量：1
  • 4Issa JP,Garcia-Manero G,Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'- deoxycytidine(decitabine) in hematopoietic malignancies.Blood, 2004, 103:1635-1640. 被引量：1
  • 5Mund C,Hackanson B,Stresemann C,et al.Characterization of DNA demethylation effects induced by 5-aza-2'-deoxyeytidine in patients with myelodysplastic syndrome.Cancer Res, 2005, 65:7086-7090. 被引量：1
  • 6Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypometylating agent 5-aza-2 - deoxycytidine (decitabine)in hematopoieticmalignancies. Blood, 2004, 103: 1635-1640. 被引量：1
  • 7Kantarian HO, Brien S, Giles F, et al. Decitabine low dose Schedule (100 mg/m2/coume) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. 2010 ASH, Annual Meeting Abstract 2522. 被引量：1
  • 8柴铁,李骏,褚金龙,果丽实.低剂量FLAG方案治疗难治性老年人急性髓系白血病12例[J].白血病．淋巴瘤,2008,17(6):457-459. 被引量：2
  • 9高冲,陈宝安,刘苒,徐昕,丁家华,王骏,程坚,赵刚,余正平,宋慧慧,鲍文.地西他滨治疗骨髓增生异常综合征一例报告[J].现代医学,2010,38(2):189-190. 被引量：10
  • 10梁虹,赵海军.CAG预激方案治疗急性髓系白血病及骨髓增生异常综合征[J].白血病．淋巴瘤,2010,19(10):607-609. 被引量：14

共引文献20

同被引文献31

  • 1高然,于锦香,高峰,蔡大利,王柏勋,潘登,张蕊,颜晓菁,李艳.地西他滨联合半量CAG治疗复发难治性急性髓细胞白血病的疗效分析[J].医学临床研究,2013,30(6):1125-1126. 被引量：1
  • 2Yamada K, Furusawa S, Saito K, etal. Concurrent use of granuloeyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia, 1995, 9: 10-14. 被引量：1
  • 3Ghoshal K, Bai S. DNA methyhransferases as targets for cancer therapy[J]. Drugs Today, 2007, 43: 395-422. 被引量：1
  • 4Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation[J]. N Engl J Med, 2003, 349: 2042-2054. 被引量：1
  • 5Issa JP, Gharibyan V, Cortes J. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate[J]. J Clin Oneol, 2005, 23: 3948-3956. 被引量：1
  • 6Chowdhury S, Sweopian S, Marks PW. Deeitabine combined with fraetionated gemtuzumab ozogamiein therapy in patients with relapsed or refractory acute myeloid leukemia[J]. Am J Hemaotol, 2009, 84: 599-600. 被引量：1
  • 7Scandura JM, Roboz G J, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML[J]. Blood, 2011, 118: 1472-1480. 被引量：1
  • 8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia [J]. Ann Hematol, 2012, 91: 1879-1886. 被引量：1
  • 9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabinc and decitabine in combination in human leukemic cell lines [J]. Clin Cancer Res, 2007, 13: 4225-4232. 被引量：1
  • 10Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia[J]. Blood, 2006, 107: 3481-3485. 被引量：1

二级引证文献43

白血病．淋巴瘤
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部